"MABPHARM" achieved a net profit of 57.13 million RMB for the entire year, turning a loss into a profit

MABPHARM-B (02181.HK) announced its 2025 annual performance, with operating revenue of 646 million RMB (same below), an increase of 150.2% year-on-year. It recorded a net profit of 57.13 million yuan, compared to a loss of 128 million yuan in the previous year, turning from loss to profit; earnings per share of 1 cent. No final dividend is declared